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The gut microbiome, composed of the microﬂora that inhabit the gastrointestinal tract and their ge-
nomes, make up a complex ecosystem that can be disrupted by antibiotic use. The ensuing dysbiosis is
conducive to the emergence of opportunistic pathogens such as Clostridium difﬁcile. A novel approach to
protect the microbiome from antibiotic-mediated dysbiosis is the use of beta-lactamase enzymes to
degrade residual antibiotics in the gastrointestinal tract before the microﬂora are harmed. Here we
present the preclinical development and early clinical studies of the beta-lactamase enzymes, P3A,
currently referred to as SYN-004, and its precursor, P1A. Both P1A and SYN-004 were designed as orally-
delivered, non-systemically available therapeutics for use with intravenous beta-lactam antibiotics. SYN-
004 was engineered from P1A, a beta-lactamase isolated from Bacillus licheniformis, to broaden its
antibiotic degradation proﬁle. SYN-004 efﬁciently hydrolyses penicillins and cephalosporins, the most
widely used IV beta-lactam antibiotics. In animal studies, SYN-004 degraded ceftriaxone in the GI tract of
dogs and protected the microbiome of pigs from ceftriaxone-induced changes. Phase I clinical studies
demonstrated SYN-004 safety and tolerability. Phase 2 studies are in progress to assess the utility of SYN-
004 for the prevention of antibiotic-associated diarrhea and Clostridium difﬁcile disease.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The gut microﬂora and their collective genomes, referred to as
the microbiome, play a key role in health and disease. The gut
microbiome works symbiotically with the body to aid digestion,
facilitate the absorption of nutrients, synthesize vitamins, block the
invasion of pathogenic bacteria across the intestinal mucosalea; CDI, Clostridium difﬁcile
centration; CRO, ceftriaxone;
stinal; IV, intravenous; MIC,
9605 Medical Center Drive,
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r Ltd. This is an open access articlebarrier, and provide protection against virulent organisms [1,2].
Recent evidence has demonstrated that the inﬂuence of the gut
microbiome is far reaching, affecting immune, metabolic, cardio-
vascular, and neurological functions [3]. Alterations or imbalances
in the ecology of the gut, termed dysbiosis, have been linked to a
variety of disease states including obesity, allergies, asthma, autism,
and a rapidly growing list of other conditions [3e5]. In fact, the gut
microbiome functions like an organ [3], and our understanding of
its role in human physiology is still evolving.
Anything that disrupts the normal ecology of the gut micro-
biome can have a negative impact on human health. While anti-
biotics are life-saving, their use is associated with dysbiosis in the
GI tract, which can increase susceptibility to pathogens such as
Clostridium difﬁcile [4,6,7] and lead to overgrowth of resistant
bacteria [8e10]. Beta-lactams are the most commonly usedunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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IV antibiotic use in the United States annually [11]. The most
frequently prescribed beta-lactams are piperacillin, including
piperacillin/tazobactam, and ceftriaxone, both of which are asso-
ciated with an increased risk of C. difﬁcile infection (CDI), particu-
larly the latter [12].
Current treatments for CDI remain relatively limited, with
metronidazole and vancomycin still the cornerstones of therapy.
Antibiotic-mediated treatment of CDI is characterized by high rates
of recurrence [13]. Recognition of the importance of the gut
microbiome in prevention of CDI has prompted investigation into
therapies aimed at restoring the normal microbial balance, such as
the use of probiotics [3] and fecal microbiota transplantation (FMT)
[14,15]. FMT reconstitutes the gut microﬂorawith organisms native
to the fecal donor and therefore does not necessarily re-establish
the patient’s pre-disease microbiome. As it is becoming increas-
ingly apparent that host genetics inﬂuence the structure of the
microbiome, and that the gut microbiome affects many, if not all
organ systems, the long-term outcomes of FMT must be carefully
evaluated [14,15]. While each of these interventions provides
treatment for CDI once the infection is established, prevention of
antibiotic-associated dysbiosis may represent a complementary
strategy to preclude the occurrence of CDI.
One novel strategy to protect the microbiome from antibiotic-
mediated dysbiosis and to prevent CDI is the use of beta-
lactamase enzymes to degrade the antibiotics in the GI tract.
1.1. Beta-lactamases: from enemies to therapies
Beta-lactamases are natural enzymes that degrade beta-lactam
antibiotics, confer antibiotic resistance, and dramatically compli-
cate the treatment of bacterial infections. Thus, they are rightfully
considered the “enemy”, and substantial efforts have been directed
towards their characterization and inhibition [16]. However, beta-
lactamases can also be harnessed as therapeutics to protect the
“good”, commensal gut microﬂora from unwanted damage
incurred by antibiotic use. In 1999, Ipsat Therapies, OY (Helsinki,
Finland) had the foresight to recognize that an orally administered
beta-lactamase had the potential to degrade residual antibiotics in
the proximal GI tract, before they could adversely affect the colonic
microﬂora. The ensuing beta-lactamase treatment, termed P1A,
was designed to be used in conjunction with parenterally admin-
istered beta-lactam antibiotics, which are secreted through the
biliary system into the proximal small intestine.
P1A is a naturally-occurring penicillinase isolated from Bacillus
licheniformis (the PenP protein) [17]. It wasmanufactured in Bacillus
subtilis and formulated into pellets with a Eudragit®-based, acid-
resistant coating for oral delivery [18]. Multiple animal and hu-
man studies demonstrated that P1Awas released in the proximal GI
tract and effectively degraded residual penicillins [18,19]. In mice,
P1A prevented colonization by pathogenic organisms including
C. difﬁcile, vancomycin-resistant Enterococcus faecium (VRE), Kleb-
siella pneumoniae and Candida glabrata [20,21]. In dogs, P1A efﬁ-
ciently degraded residual ampicillin in the intestinal ﬂuid, chyme,
while having no effect on serum ampicillin levels [22]. Additionally,
P1A protected the gut microbiome from antibiotic-mediated
disruption [19,23] and prevented the selection of ampicillin-
resistant bacteria [18,24].
Based on these promising preclinical efﬁcacy data, P1A was
subsequently evaluated in four successful Phase 1 and 2 clinical
trials conducted in Europe [18,19]. In healthy human subjects and
hospitalized patients with upper respiratory tract infections treated
with IV ampicillin, P1A preserved microbiome diversity and pre-
vented the emergence of ampicillin-resistant coliforms [18]. Simi-
larly, in healthy volunteers treated with IV piperacillin/tazobactam,P1A effectively degraded pipercillin in the GI tract, preserved the
microbiome, and prevented the occurrence of antibiotic-associated
diarrhea [19]. Importantly, P1A was not detected in the plasma of
treated subjects and had no effect on plasma levels of pipercillin
[19]. Taken together, these data demonstrate the clinical utility of
this novel therapeutic approach in protecting the microbiome from
antibiotic-mediated damage without affecting systemic antibiotic
efﬁcacy. However, as a penicillinase, the clinical utility of P1A was
limited. P1A did not efﬁciently degrade most cephalosporins
including ceftriaxone, which is the most frequently used IV beta-
lactam antibiotic [11] and is associated with a high risk for CDI
[12]. In 2012, Synthetic Biologics, Inc. acquired the beta-lactamase
technology, including a second generation product candidate,
P3A. Now referred to as SYN-004, P3A was engineered from P1A
with the intent of broadening its antibiotic degradation proﬁle to
include cephalosporins. SYN-004 is currently undergoing Phase 2
clinical analyses [25]. Here, we report the data supporting the
clinical application of SYN-004.
2. Methods
2.1. Production of beta-lactamases
P1A was manufactured in B. subtilis as described [22]. SYN-004,
a protein of 29 kDa, was manufactured in Escherichia coli. SYN-004
was formulated for oral delivery by incorporation into Eudragit®-
coated sucrose pellets designed to release active enzyme at pH 5.5
or greater [26]. The pellets contained approximately 15% SYN-004
[26]. Gelatin capsules suitable for oral delivery were ﬁlled with
the pellets for a total SYN-004 content of 75 mg/capsule.
2.2. In vitro antibiotic degradation analyses
The antibiotic degradation kinetics of P1A and SYN-004 en-
zymes were determined for ampicillin, amoxicillin, piperacillin,
ceftriaxone, cefazolin, cefuroxime, cefoperazone, and cefotaxime.
The steady-state Km and kcat values for each antibiotic were
determined by measuring substrate hydrolysis under initial rate
conditions with Hanes linearization [27] of the Michaelis-Menten
equation. The reactions were performed in 20 mM phosphate
buffer (pH 7.0) at 30 C. Brieﬂy, dilutions of each antibiotic were
prepared in sodium phosphate buffer and distributed to individual
wells of a 96-well plate. The plate was pre-incubated at 30 C for
5 min, after which P1A (1.0 nM) or SYN-004 (1.0 nM) was added to
the plate. The absorbance at 235 nm (ampicillin and piperacillin),
242 nm (amoxicillin), 257 nm (ceftriaxone), and 264 nm (cefazolin,
cefuroxime, cefoperazone, cefotaxime) of the individual wells was
determined every 5e8 s over a 10e20min period of incubation. The
initial velocity was calculated as the change in absorbance per min
(mUabs/min) of the reaction as determined using SoftMax Pro 5.4
software from the slope of the curve within the linear range of the
reaction. Following the kinetic analysis, an endpoint reading was
taken to determine the pathlength (cm) of the specimen in each
individual well. The velocity (mUabs/min) values were normalized
to a 1 cm pathlength by dividing the values by the measured
pathlength. The normalized velocity values (mUabs/min-cm) were
then converted to velocity (nmole/sec-cm) using an experimentally
determined extinction coefﬁcient speciﬁc for each individual anti-
biotic at the given wavelength. The data were imported into Prism
GraphPad 5 for determination of Michaelis-Menten kinetics by
non-linear regression. The analysis was performed a minimum of 3
times for each antibiotic substrate. Kinetic data (Km, kcat, and kcat/
Km) were calculated from the mean of the experiments. Data are
presented as the mean ± standard deviation.
The antibiotic inactivation activities of P1A and SYN-004 were
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designed to mimic the activity of the beta-lactamases in the gut in
the presence of high antibiotic concentrations. The degradation of
the antibiotics Amp, ampicillin; CRO, ceftriaxone; CFZ, cefazolin;
CXM, cefuroxime; CFP, cefoperazone; FEP, cefepime; CTX, cefotax-
ime; and CAZ, ceftazidimewere evaluated. Puriﬁed P1A or SYN-004
(10 or 100 ng/mL) was added to wells of a microtiter plate con-
taining high antibiotic concentrations (10,100, or 1000 mg/mL) after
which E. coli (ATCC strain 25922) were immediately added. The
beta-lactamase activity of each culture supernatant was deter-
mined as positive or negative based on the appearance of bacterial
growth in the individual wells. An OD625 of 0.8 or greater indicated
maximal bacterial growth, therefore complete antibiotic degrada-
tion and high beta-lactamase activity. An OD625 of less than 0.8
indicated low bacterial growth and, therefore, incomplete antibi-
otic degradation, hence low beta-lactamase activity. Wells with an
OD625 of 0.8, indicating full growth of the E. coli, were recorded.
The highest concentration of antibiotic that was inactivated by the
beta-lactamase present in each well is represented on the bar
graph. The assay, therefore, was read as a growth or no growth
endpoint. Analyses were performed in duplicate wells, and the
studies were repeated at least twice for each beta-lactamase and
antibiotic concentration. In the rare instance of a disparity in bac-
terial growth between duplicate wells, the analyses were repeated.
2.3. In vitro dissolution and human chyme studies
For the dissolution analyses, SYN-004 enteric-coated pellets
were held in a pH 1.0 solution for 2 h after which the pH was raised
to 5.5, 5.8, or 6.8. Samples collected at the indicated times over 4 h
were assessed for SYN-004 biological activity using the chromo-
genic cephalosporin, CENTA, as the substrate, as described [28].
Human chyme, collected from 5 different donors, was obtained
from the Oklahoma Foundation for Digestive Research (OFDR), an
Oklahoma not-for-proﬁt corporation. Human chyme samples were
characterized by pH, liquid content, and protease activity. Protease
activity of the chyme specimens was determined using a com-
mercial Protease Activity Fluorometric Assay Kit (Biovision, Milpi-
tas, CA) following the manufacturer’s recommended procedures.
Chyme specimens were diluted 1:20 in protease assay buffer prior
to performing the protease assay. The pHs ranged from 5.58 to 6.56,
liquid content ranged from 55% to 78%, and protease activity ranged
from 5.57 to 8.96 mU/mL. SYN-004 enteric-coated pellets were
mixed with the ﬁve individual human chymes. Samples collected
over a 6 h period were assessed for SYN-004 biological activity
using the chromogenic cephalosporin, CENTA, as the substrate, as
described [28].
2.4. Animal studies
All animal studies were performed with adherence to animal
use guidelines and with the required institutional animal assur-
ances. Dog studies were performed at Ipsat, OY (Helsinki, Finland)
as described [22]. Pig studies were performed at Tufts University
(North Grafton, MA) as described [29]. Brieﬂy, jejunal-ﬁstulated
dogs (n ¼ 6) received IV ceftriaxone (30 mg/kg) alone or
ceftriaxone þ oral SYN-004 enteric-coated pellets (0.44 mg/kg) in
two serial studies on separate days. The animals were fed shortly
before dosing and then again 6 h later; however, two of the dogs did
not eat prior to antibiotic dosing in the second study with
ceftriaxoneþ SYN-004. Ceftriaxone and SYN-004weremeasured in
the chyme at the indicated times over 10 h. Animal dosing and
sample collections, and beta-lactamase and ceftriaxone assayswere
performed as described [22e24,26].
Pigs (n ¼ 7) were delivered via Caesarian section and housedseparately in microisolator cages to maintain them as gnotobiotic
animals [30]. Five days after birth (day 5), the GI tract was popu-
lated with human adult fecal microﬂora as described [29], and on
day 8, the appropriate animals (approximately 1 kg each), received
SYN-004 (75 mg capsule, PO, QID) for 7 consecutive days (days
8e14). On day 9, animals received ceftriaxone (50mg/kg, IP, SID) for
4 consecutive days (days 9e12). The cohorts were untreated (n¼ 2,
but one animal was sickly and did not continue in the study), cef-
triaxone alone (n ¼ 2), and ceftriaxone þ SYN-004 (n ¼ 3). Feces
were collected directly from the rectum using sterile swabs on days
14, 20, and 21. Dilutions of day 20 fecal samples were plated on
LBþ ampicillin plates and incubated overnight. Distinct colonies on
plates from equal feces dilutions were counted.
For microbiome analyses, DNA was isolated from day 14
(designated T1) and day 21 (designated T2) fecal samples and
subjected to 16S and/or shotgun deep sequencing analyses. The 16S
sequencing was performed with the day 14 fecal DNA using
HiSeq2000 Illumina sequencer with an average of 4 million 250
nucleotide single reads with 3000 sequences randomly selected
from each sample as described [29]. Data analyses were performed
using open-source software Mothur version 1.25 as described [29].
Shotgun sequence analyses were performed on fecal DNA from day
14 and day 21 samples (designated gDNA, Fig. 5A) as well as
additional DNA isolated from frozen day 21 feces (designated Fecal,
Fig. 5A). Shotgun sequencing was performed using Illumina HiSeq
RAPID RUN, targeting 100 bp single reads to achieve 10 million
reads per sample. Sequenced datasets were taxonomically classi-
ﬁed using the GENIUS® software package [31,32]. Heatmaps were
created based on the log of the relative abundance of bacteria
strains in each sample using the NMF R package [33]. Samples were
grouped using the maximum distance function and the Ward hi-
erarchical clustering algorithm to create a dendrogram grouping
samples with similar compositions into clades. The centroid clas-
siﬁcation method from the pamr R package [34] was used to
compare the average frequency (absolute abundance) of each
bacterial strain in the samples. The deviation of the centroid of each
bacterial strain from each study cohort from the overall average
frequency of all study groups was calculated.
3. Results
3.1. Beta-lactamase antibiotic degradation proﬁle
P1A, a naturally occurring beta-lactamase enzyme was engi-
neered to broaden its antibiotic degradation proﬁle to include
cephalosporins such as ceftriaxone. This modiﬁed beta-lactamase,
originally designated P3A, is currently referred to as SYN-004. To
generate SYN-004, the negatively charged aspartic acid at position
276 using the Ambler numbering system for class A beta-
lactamases [35] was replaced with a neutral amino acid, aspara-
gine. This one amino acid substitutionwas the only change made to
the molecule and was intended to change the structure of the beta-
lactamase enzyme. Speciﬁcally, the aspartic acid forms a salt bond
with an arginine at position 244, proximal to the active site of the
enzyme. The asparagine substitution at 276 was expected to alter
the interaction with the arginine to enlarge the enzymatic cavity
and to potentially accommodate a broader range of beta-lactam
substrates.
To determine if this one amino acid substitution changed the
antibiotic degradation proﬁle of SYN-004 compared to P1A, two
in vitro analyses including kinetic studies and a microtiter plate
bacterial growth assay were performed. The kinetic parameters of
the P1A and SYN-004 enzymes were determined for hydrolysis of a
series of beta-lactam antibiotic substrates (Fig. 1A). The Km, kcat and
kcat/Km values calculated for SYN-004 were similar to P1A for
Fig. 1. Antibiotic Degradation Proﬁles of P1A and SYN-004. Hydrolysis of the indicated beta-lactam antibiotics was evaluated by kinetic analyses and with a bacterial growth
microtiter plate assay. A) Kinetic parameters of P1A and SYN-004 enzymes. The steady-state Km and kcat values for the indicated beta-lactam antibiotics were determined by
measuring substrate hydrolysis under initial rate conditions with Hanes linearization [27] of the Michaelis-Menten equation for the indicated beta-lactam antibiotics. B) E. coli
growth microtiter plate assay. Puriﬁed P1A or SYN-004 (10 or 100 ng/mL) was added to wells of a microtiter plate containing high antibiotic concentrations (10, 100, or 1000 mg/mL)
after which E. coli were immediately added. Bacterial growth, an indication of antibiotic inactivation, was measured (OD625) the next day. The data represent the highest con-
centration of antibiotic that was inactivated by the beta-lactamase. Amp, ampicillin; CRO, ceftriaxone; CFZ, cefazolin; CXM, cefuroxime; CFP, cefoperazone; FEP, cefepime; CTX,
cefotaxime; CAZ, ceftazidime. Data presented in part at ICAAC 2014 [55].
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amino acid substitution did not adversely affect hydrolysis of the
penicillins. Notably, SYN-004 displayed a marked improvement for
the hydrolysis of ceftriaxone. Whereas the kcat/Km was 157 for P1A,
it was 50-fold higher at 8554 for SYN-004 (Fig. 1A). Therefore, the
single amino acid substitution generated a beta-lactamase enzyme
that efﬁciently degraded penicillins and exhibited improved ki-
netics for ceftriaxone.
While the kinetic analyses revealed a broader degradation
proﬁle for SYN-004, it was not readily apparent how to use these
parameters to predict in vivo efﬁcacy. Thus, a second in vitro assay
was developed to more closely model the in vivo enzyme re-
quirements. This microtiter plate assay mixed the beta-lactamases
with various antibiotics and used bacterial growth as a readout for
antibiotic degradation. Low concentrations of the beta-lactamase
enzyme (10 and 100 ng/mL) were mixed with high concentra-
tions of the antibiotics, (10, 100 or 1000 mg/mL) in microtiter wells.
Bacteria were immediately added and bacterial growth was
measured the next day. Bacterial growth indicates that the beta-
lactamase inactivated the antibiotic. Thus, this assay was scored
using a growth or no growth endpoint. The bars on the graph
represent the highest concentration of each antibiotic that was
inactivated by the beta-lactamase (Fig. 1B). Consistent with the
kinetic data (Fig. 1A), P1A and SYN-004 were equally effective
against ampicillin, again verifying that the one amino acid substi-
tution did not affect degradation of the penicillins. SYN-004 was
more efﬁcient in the degradation of ceftriaxone as well as the other
cephalosporins, cefazolin, cefuroxime, cefoperazone, and, at a
higher concentration, cefotaxime and ceftazidime. Cefepime, as an
exception, was hydrolyzed equally well by P1A and SYN-004. Based
on its improved degradation of cephalosporins, SYN-004 is antici-
pated to have broader utility for protection of the intestinal
microbiome.
3.2. SYN-004 stability in human chyme
In contrast to P1A, which was manufactured in B. subtilis [22],
SYN-004 was produced in E. coli [26]. This change in manufacturing
platform improved process yields from ~1 g/L to 14 g/L [36]. A
puriﬁcation strategy that includes one chromatographic stepproduced ﬁnal yields of ~45% with >95% purity [36]. For protection
from stomach acid, SYN-004 was incorporated into Eudragit®-
coated sucrose pellets designed for release at pH 5.5 [26,36].
Compared to the original P1A pellets [18], the SYN-004 formulation
was modiﬁed to increase drug loading and reduce the Eudragit®
content [26]. The pellets were conﬁrmed to be uniform spheres of
~1 mm diameter by electron microscopy and were used to ﬁll
capsules suitable for oral delivery [26,36]. To verify pH-based
dissolution, SYN-004 pellets were held in a 0.1 N HCl solution for
2 h followed by incubation in buffers at varying pHs for 4 h (Fig. 2A)
[36]. SYN-004 pellets were protected at low pH while dissolution
occurred at pHs >5.5, with pHs of 5.8 and 6.8 showing more rapid
dissolution than pH 5.5. Therefore, these data conﬁrm that the
enteric coating remained intact at low, stomach pH and active beta-
lactamase enzyme was released at pH > 5.5, the pH levels found in
the duodenum.
Resistance to degradation by intestinal proteases is a key attri-
bute for beta-lactamases intended for GI-targeted therapy. To
determine if SYN-004 retained biological activity in human intes-
tinal ﬂuid, SYN-004 enteric-coated pellets were incubated in hu-
man jejunal ﬂuid, chyme, and then evaluated for biological activity
(Fig. 2B). Human chyme was collected from ﬁve donors with
ileostomies and was characterized based on pH, liquid content, and
protease activities. SYN-004 pellets were incubated in each chyme
sample, and aliquots taken over 6 h were assessed for biological
activity. As expected, based on the initial pH dissolution studies
(Fig. 2A), SYN-004 pellets dissolved rapidly, within 30e60 min, in
human chyme. Notably, SYN-004 biological activity was main-
tained at high levels for at least 6 h in the ﬁve chyme samples
(Fig. 2B). These data suggest that enteric-coated SYN-004 will
retain activity in the GI tract for a sufﬁcient period to degrade re-
sidual beta-lactam antibiotics and protect the downstream
microbiota.
3.3. Efﬁcacy of SYN-004 in a canine model
To assess the ability of SYN-004 to degrade antibiotics in the GI
tract, six jejunal-ﬁstulated dogs were subjected to two serial
studies on separate days. In the ﬁrst study, each dog received IV
ceftriaxone alone. In the second study, the dogs received the IV
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mals were fed shortly before dosing and then again 6 h later. In the
ﬁrst study, with ceftriaxone alone, the antibiotic was excreted at
high levels into the intestine with a ﬁrst peak at 100 min and a
second peak 6 h later, after the additional feeding. The mean Cmax
for the two peaks were 1500 mg/g of chyme (range of
1020e2760 mg/g of chyme) and 167 mg/g (range of 49e440 mg/g of
chyme), respectively. As ceftriaxone is excreted into the duodenum
through the bile, and bile is released after eating, the second peak
was likely due to residual biliary ceftriaxone. In the second study,
SYN-004 was rapidly detected in the chyme from 4 of the 6 dogs
(peak from 12.6 to 30.9 mg/g of chyme) and the ceftriaxone con-
centrations remained low (<5 mg/g chyme) for at least 5 h (Fig. 3,
left panels). Interestingly, even though SYN-004 became unde-
tectable (<0.1 mg/g of chyme) by 6 h, the second ceftriaxone peak
was also noticeably reduced. The other 2 dogs did not eat prior to
antibiotic dosing. Only one of these animals produced enough
chyme for both the ceftriaxone and beta-lactamase analyses. The
analyzed dog exhibited slower accumulation of SYN-004 in the
chyme, presumably due to delayed gastric emptying. Not unex-
pectedly, the ﬁrst ceftriaxone peak was present in the chyme, but
the second peak was substantially reduced (Fig. 3, right panels).
These data indicate that, whenever SYN-004 was present in the
small intestine, it efﬁciently eliminated ceftriaxone from the
chyme. Moreover, the SYN-004 remained functional for more than
8 h, the duration that antibiotic was released into the intestine.
Finally, the timing with which SYN-004, and perhaps the antibiotic,
enter the small intestine may be variable. Thus, SYN-004 should be
dosed more frequently than once per day to ensure its continuous
presence in the GI tract.3.4. SYN-004 protects the intestinal microﬂora of humanized
gnotobiotic pigs
SYN-004 was evaluated in “humanized” neonatal pigs [29] to
assess its capacity to prevent antibiotic-induced microbiome
changes. In this pilot study with limited cohort sizes, the GI tracts of
5 day old gnotobiotic pigs were populated with human adult fecal
microﬂora and randomly assigned to experimental groups: no
antibiotic treatment; ceftriaxone alone; and ceftriaxoneþ SYN-004
[37,38]. Ceftriaxone was administered by intraperitoneal injection
once each day for four days, and SYN-004 was delivered orally fourFig. 2. SYN-004 Enteric-Coated Pellet Dissolution and Stability Proﬁles. A) SYN-004 enteric-c
5.8, or 6.8. Samples collected over 4 h were assessed for SYN-004 biological activity using th
pellets were mixed with human chyme obtained from 5 different donors. Samples collecte
chyme sample is displayed. Data presented in part at IDWeek 2014 [36].times a day for seven days beginning one day before the ceftriax-
one. Protection of the fecal ﬂora and microbiome from antibiotic-
mediated dysbiosis was monitored in several ways.
First, levels of ampicillin-resistant facultative aerobes were
quantiﬁed by counting colonies on LB þ Amp plates (Fig. 4A). This
speciﬁc subset of fecal bacteria, which includes the phylum Pro-
teobacteria, was chosen based on its anticipated sensitivity to cef-
triaxone. As expected, the colony counts from the animals that
received ceftriaxone alone were two orders of magnitude lower
than those from the no antibiotic control animal. Notably, when
SYN-004 was administered with the ceftriaxone, the colony counts
were as high as those of the control. Thus, SYN-004 protected the
fecal bacteria from ceftriaxone.
Second, to obtain a phylum-level taxonomic classiﬁcation of the
GI microﬂora, fecal DNA samples collected 2 days after the antibi-
otic was stopped were subjected to 16S rRNAV6 region sequencing
(Fig. 4B). The 16S sequence analyses revealed that the bacterial
proﬁle from the no antibiotic control animal comprised Bacter-
oidetes, Proteobacteria, and Firmicutes, while the proﬁles from the
ceftriaxone alone cohort were distorted, with Bacteroidetes as the
most predominant phylum (Fig. 4B). When SYN-004 was admin-
istered along with the ceftriaxone, the fecal bacteriawere protected
from the antibiotic and maintained 16S proﬁles similar to the
control. As predicted from the colony count data (Fig. 4A), Proteo-
bacteria were underrepresented in the ceftriaxone-alone animals
but were preserved in the animals treated with SYN-004.
To further assess the microbiome of the neonatal pigs, whole
genome shotgun sequencing was performed using the pig fecal
DNA samples (Fig. 5). Heatmaps of the bacterial taxa were con-
structed based on the relative abundance of each bacterial strain
and a dendrogram was generated with the Ward hierarchical
clustering algorithm to group samples with similar compositions
into clades. The data revealed that the no antibiotic control and
ceftriaxone þ SYN-004 samples were clustered together while
samples from the animals treated with ceftriaxone alone formed a
separate clade (Fig. 5A). Thus, the bacterial populations in the
control and ceftriaxone þ SYN-004 groups were more similar to
each other than to those in the ceftriaxone alone group.
The sequencing data were also analyzed using the nearest
shrunken centroid classiﬁcation [34] to compare the average de-
viation of the frequency of each bacterial species among the sam-
ples within each cohort to the overall average frequency of all studyoated pellets were held in a pH 1.0 solution for 2 h after which the pH was raised to 5.5,
e chromogenic cephalosporin, CENTA, as the substrate [28]. B) SYN-004 enteric-coated
d over 6 h were assessed for SYN-004 biological activity as described. The pH of each
Fig. 3. SYN-004 Degrades Ceftriaxone (CRO) in the GI Tract of Dogs. Jejunal-ﬁstulated dogs (n ¼ 6) received IV ceftriaxone (30 mg/kg) alone (top panels), or ceftriaxone þ oral SYN-
004 enteric-coated pellets (0.44 mg/kg) (middle and bottom panels). Ceftriaxone (top and bottom panels) and SYN-004 (middle panels) were measured in the chyme at the
indicated times over 10 h. The left panels represent the four dogs that ate prior to antibiotic dosing, and the right panels represent one animal that did not eat prior to antibiotic
dosing. Data from each individual animal is provided in the Supplemental Materials. Data presented in part at IDWeek 2014 [36].
M. Kaleko et al. / Anaerobe 41 (2016) 58e67 63groups (Fig. 5B). The SYN-004 þ ceftriaxone cohort displayed less
severe distortion of species abundance compared to the ceftriaxone
alone cohort. Likewise, the no antibiotic control and
ceftriaxone þ SYN-004 cohorts were more similar to each other
than to the ceftriaxone alone cohort. Interestingly, in the ceftriax-
one alone cohort, the methanogen,Methanobrevibacter smithii,was
overrepresented while Turicibacter spp. were underrepresented
compared to the control and ceftriaxone þ SYN-004 cohorts.
Overgrowth of M. smithii was reported to be associated with con-
stipation and irritable bowel syndrome as well as obesity in
humans [39], while reduction of Turicibacter spp. was associatedFig. 4. SYN-004 Maintains the Diversity of Human Intestinal Microﬂora in Pigs. Pigs (n ¼ 6)
days after birth (day 5), the GI tract was populated with human adult fecal microﬂora [
ceftriaxone þ SYN-004, or left untreated. A) Bacterial colony counts of day 20 feces plated on
sequences from DNA isolated from feces collected two days after antibiotics were st
ceftriaxone þ SYN-004. Data presented in part at DDW 2015 [37], and ICAAC 2015 [38].with idiopathic inﬂammatory bowel disease and acute hemor-
rhagic diarrhea in dogs [40,41].
Taken together, both the 16S and whole genome sequencing
data demonstrate that SYN-004 protected the gut microﬂora from
the adverse effects of antibiotic use and maintained the micro-
biome diversity. Further studies are in progress using normal ju-
venile pigs to conﬁrm the results of this pilot study.
4. Discussion
The intestinal microbiome plays a signiﬁcant role in regulatingwere delivered via Caesarian section and housed separately in microisolator cages. Five
28], and four days later the indicated animals were treated with ceftriaxone alone,
LB þ ampicillin plates. B) Phylum-level taxonomic classiﬁcation of 16S rRNA V6 region
opped (day 14). No Abx, no antibiotic; CRO, ceftriaxone alone; CRO þ SYN-004,
M. Kaleko et al. / Anaerobe 41 (2016) 58e6764human physiology and preserving health. Whereas microbiome
functionwas once relegated to aiding digestion and protecting from
colonization by potential pathogens, it is now recognized to
modulate host immune, metabolic, cardiovascular, and neurologic
activities [3e5]. Thus, preserving a patient’s native microbiome can
be considered a high medical priority. Unfortunately, when anti-
biotics are used to treat serious infections, they can enter the GI
tract and damage the native microﬂora. Recovery from this collat-
eral damage can require protracted times, and some bacterial
species may be permanently lost [6,7].
SYN-004 has the potential to protect the GI microbiome from
beta-lactam antibiotics. The most tangible application for this
technology is the prevention of antibiotic-associated C. difﬁcile
infection. In this regard, SYN-004 has a major advantage over its
predecessor, P1A, in that it extends utility to commonly used
cephalosporins. Whereas both the penicillins and cephalosporins
predispose to CDI, the risk is substantially greater with theFig. 5. SYN-004 Protects the Microbiome from Antibiotic-Mediated Changes in Pigs. Whole
DNA samples included DNA from day 14 (T1), day 21 (T2), and DNA isolated from day 21 fro
each sample. Samples were grouped using the maximum distance function and the Ward h
with similar compositions organized into clades (left side of the ﬁgure). The yellow box ill
samples clustered together in one clade. B) Nearest shrunken centroid classiﬁcation compar
within each cohort to the overall average frequency of all study groups. The species display
were underrepresented in the antibiotic-alone group. No Abx, no antibiotic; SYN-004 þ CRO
2015 [37], and ICAAC 2015 [38].cephalosporins [7,42e44]. Moreover, cephalosporins were reported
to increase C. difﬁcile acquisition during hospitalization, while
penicillins were associated with a decrease in C. difﬁcile carriage
[45]. Beyond CDI, it is noteworthy that SYN-004 has the potential to
protect patients from hospital acquired secondary infections with
other drug-resistant pathogens including both gram negative co-
liforms and gram positive cocci [20,21,46]. Antibiotic treatment can
promote gastrointestinal overgrowth of these organisms, which
can then lead to the seeding of other organs.
Based on its extended activity proﬁle, SYN-004 is anticipated to
have clinical utility for a large number of patients. In the U.S. and
E.U. intravenous beta-lactams are administered to approximately
27 million patients annually for a total of 123 million patient days
[11]. SYN-004 efﬁciently inactivates ceftriaxone and piperacillin.
These two antibiotics, including piperacillin/tazobactam, account
for approximately 50% of the beta lactam usage with 12.6 million
patients treated annually and 66 million patient days of therapygenome shotgun sequencing was performed with the pig fecal DNA samples. The fecal
zen feces (Fecal). A) Heat map of the log of the relative abundance of bacteria strains in
ierarchical clustering algorithm. A dendrogram was constructed that displays samples
ustrates that the no antibiotic control and the majority of the SYN-004 þ ceftriaxone
ing the average deviation of the frequency of each bacterial species among the samples
ed in red text, Methanobrevibacter smithii, was overrepresented, while Turicibacter spp.
, SYN-004 þ ceftriaxone; CRO alone, ceftriaxone alone. Data presented in part at DDW
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We presented data from in vitro analyses, formulation studies,
and two large animal models. The kinetic and bacterial growth
microtiter assays suggest that SYN-004 has the potential to degrade
multiple beta-lactam antibiotics, and the dissolution studies
conﬁrm that the formulated pellets will successfully traverse the
stomach to release biologically active enzyme in the duodenum.
Most importantly, the chyme stability studies demonstrate that
SYN-004 has the remarkable capacity to avoid digestion in the GI
tract, thereby circumventing a major limitation to the development
of therapeutic proteins for oral use. The canine data verify that SYN-
004 persists in the GI tract and can efﬁciently degrade ceftriaxone
in the chyme. The humanized neonatal pig data support the po-
tential to protect the microbiome from antibiotics. Importantly, the
neonatal pig data also suggest that SYN-004 degrades ceftriaxone
to levels that are sufﬁciently low, below the minimum inhibitory
concentrations (MICs), to protect much of the antibiotic-sensitive
colonic microﬂora.
The canine studies reveal the complex pharmacokinetic nuances
related to dosing. Since gastric emptying, biliary secretion, and
intestinal transit times will differ among patients, it may be difﬁcult
to coordinate the SYN-004 dosing with that of the antibiotic. This
limitation is effectively addressed by dosing more than once per
day to achieve continuous bioavailability in the GI tract. Moreover,
SYN-004 has a broad therapeutic window to enable an upward
dose adjustment if necessary. Speciﬁcally, the beta-lactamase is not
toxic to the GI tract and does not alter systemic antibiotic levels
[26,47e49]. Thus, an administration frequency and dose can be
established to mitigate patient to patient variability.
One interesting ﬁnding is that both P1A and SYN-004 are
inhibited in vitro by commonly used beta-lactamase inhibitors
including tazobactam and sulbactam [20, data not shown]. Yet P1A
was efﬁcacious in a clinical trial with piperacillin/tazobactam [19]
and in canine studies with piperacillin/tazobactam, amoxicillin/
clavulanate, and ampicillin/sulbactam [19]. While this paradoxical
result remains unexplored, it is possible that the antibiotic and the
inhibitor have different biliary pharmacokinetics such that the
antibiotic enters the duodenum separately from the inhibitor.
Alternatively, the P1A may simply have overwhelmed the inhibitor.
Importantly, these results suggest that SYN-004 may have utility
for the beta-lactam/inhibitor combinations in current use and in
development.
SYN-004 was evaluated in two canine GLP toxicology studies in
which it was well tolerated, was not systemically absorbed, and did
not affect ceftriaxone blood levels [26,47e49]. The currently
anticipated therapeutic dose is 150 mg orally four times per day.
Two Phase 1 studies were completed, which demonstrated safety
and tolerability with a single dose of up to 750 mg and multiple
doses of 300 mg four times per day for 7 days. SYN-004 was neither
systemically bioavailable nor immunogenic in humans [47e49].
Two Phase 2a Proof-of-Mechanism studies are in progress in
ileostomy patients to enable facile sampling of intestinal chyme.
Patients received ceftriaxone along with SYN-004. Plasma ceftri-
axone pharmacokinetics are being determined and chyme is being
assayed for both ceftriaxone and SYN-004. A Phase 2b study, also in
progress, is intended to evaluate the capacity of SYN-004 to reduce
the risk of CDI and antibiotic-associated diarrhea in hospitalized
patients treated with ceftriaxone for lower respiratory tract in-
fections [25].
One aspect of the beta-lactamase strategy that is currently un-
explored is the potential for CDI prophylaxis in patients who
receive multiple antibiotics, either concurrently or before/after the
course of a beta-lactam. In particular, ﬂuoroquinolones and clin-
damycin carry a high risk for CDI [7]. In the U.S., the percentage of
patients treated with ceftriaxone who concurrently receive aquinolone or clindamycin is 0.4% and 1.4%, respectively [11]. For
piperacillin/tazobactam, the data are 6.6% and 1.4%, respectively
[11]. Since the likelihood of acquiring CDI may to be roughly
correlated with the total antibiotic exposure [50], it is reasonable to
assume that removing the contribution from the beta-lactam will
diminish the total risk. Quantitative support for this hypothesis will
require future clinical evaluation.
A technology that may have potential to complement SYN-004
for patients concurrently treated with a beta-lactam and ﬂuo-
roquinolone involves the use of activated charcoal as a binding
agent. When orally administered to animals and humans, activated
charcoal was able to bind ﬂuoroquinolones in the intestines
[51e53]. However, there are potential limitations to the clinical
implementation of a charcoal-based product. First, efﬁcacy may
require a substantial amount of charcoal since the potency is
limited by its binding capacity; and second, activated charcoal has
the potential to nonspeciﬁcally bind other medications and nutri-
ents in the GI tract.
To further broaden the utility of the beta-lactamase technology,
two SYN-004 pipeline products are being developed. The ﬁrst is
designed to extend the utility of SYN-004 to use with oral antibi-
otics. This product will provide continuous microbiome protection
for hospitalized patients treated with IV beta-lactams and then
discharged on oral antibiotics. In the U.S. and E.U. 19% and 13% of
patients, respectively [11], are transitioned to oral antibiotics. This
ﬁrst pipeline product is also being designed for general outpatient
use in conjunctionwith commonly prescribed antibiotics including
amoxicillin, amoxicillin/clavulanate, and cephalexin. The second
pipeline product will expand the antibiotic degradation proﬁle to
include the carbapenems [54]. Approximately 2.8million courses of
carbapenems are prescribed annually in the U.S. and E.U. [11]. This
third class of beta-lactam antibiotic is gaining in importance due to
changing patterns of bacterial resistance.
The ultimate goal of the antibiotic inactivation strategy
described herein, and for SYN-004 in particular, is to enable a pa-
tient to leave the hospital with the same gut microbiome with
which he or she entered. In the short-term, this should provide
protection from acute illnesses such as CDI and secondary in-
fections with drug resistant pathogens. In the long-term, the
symbiotic relationship between the patient and his or her GI
microﬂora will be preserved. Finally, by mitigating the GI collateral
damage, SYN-004 has the potential to eliminate many of the risks
associated with the use of beta-lactam antibiotics.
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